The Argentinian National Institute of Industrial Property (INPI, by its acronym in Spanish) signed a bilateral agreement with the US Patent Office on February 13th that includes reciprocal acceptance of patenting results of both offices. The news are grave and serious as the "Patent Prosecution Highway Between USPTO and INPI-Argentina" effectively repeals the Argentine Patent
BUENOS AIRES, December 15th 2015 - Fundación Grupo Efecto Positivo (FGEP), an organization whose work is focused on guaranteeing access to essential medicines for HIV and Hepatitis C in Argentina and Latin America, announced in a press conference on November 30th two new key actions to defend public health policies. Dr. Daniel Gollán, Argentina’s Minister
The Argentine Community of People Living with HIV requested the rejection of a patent for an essential HIV/AIDS medicine. If the Argentine Patent Office does grant the this request, Argentina could produce generic versions at a lower cost representing a potential saving of over US$11 million. Argentina April 13th, 2015.- The Grupo Efecto Positivo Foundation (FGEP) in collaboration with the Argentine
BUENOS AIRES – On Tuesday July 21st members of Fundación GEP met with the head of the Ministry of Industry, Lic. Débora Giorgi, and the President of the National Institute of Industrial Property (INPI) Cdor. Mario Aramburu, to analize the topics of the joint agenda on access to medicines and intellectual property. Among these were reviewed the presentations
Organizations of people with hepatitis C have filed an opposition for a patent that would prevent 800,000 people from having access to treatment in Argentina Fundación Grupo Efecto Positivo (FGEP) leads the opposition to pharmaceutical patents movement as a key strategy to ensure access to medicines The growing global movement to guarantee access to medicines